Eli Lilly (LLY) closed at $243.75 in the latest trading session, marking a +1.07% move from the prior day.
Eli Lilly and Company (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Merck (NYSE: MRK) and its partner, Ridgeback Biotherapeutics, hope to soon win U.S. Emergency Use Authorization (EUA) for the first COVID-19 pill. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss the potential impact of Merck's pill on COVID-19 antibody therapies.